ChinaBio Today -- Pfizer will use acquisitions and partnerships in an effort to become the number one drug seller in emerging markets such as China. Currently, Pfizer occupies the number three position. The emerging markets sector is worth $80 billion currently, and is expected to grow to $120 billion by 2012. Asked if acquisitions figured in the company’s future, Jean-Michel Halfon, President of Emerging Markets for Pfizer replied, “We see opportunities coming from the financial crisis ... opportunities to build partnerships in emerging markets.”
